Detalles de la búsqueda
1.
Inefficacy of a highly selective T-type calcium channel blocker in preventing atrial fibrillation related remodeling.
J Cardiovasc Electrophysiol;
25(5): 531-536, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24330029
2.
Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor.
Bioorg Med Chem Lett;
23(1): 119-24, 2013 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23200256
3.
Assessment of ventricular repolarization variability with the DeltaT50 method improves identification of patients with congenital long QT syndromes.
Ann Noninvasive Electrocardiol;
18(3): 240-50, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23714082
4.
Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.
J Mol Cell Cardiol;
52(5): 998-1008, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22353256
5.
Discovery of N-(1-adamantyl)-2-(4-alkylpiperazin-1-yl)acetamide derivatives as T-type calcium channel (Cav3.2) inhibitors.
Bioorg Med Chem Lett;
21(18): 5557-61, 2011 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21782423
6.
DeltaT50--a new method to assess temporal ventricular repolarization variability.
J Electrocardiol;
44(4): 477.e1-9, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21704223
7.
Model systems for the discovery and development of antiarrhythmic drugs.
Prog Biophys Mol Biol;
98(2-3): 328-39, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-19038282
8.
Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre.
Eur J Pharmacol;
558(1-3): 133-43, 2007 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-17198698
9.
A novel approach to data processing of the QT interval response in the conscious telemetered beagle dog.
J Pharmacol Toxicol Methods;
55(1): 35-48, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-16581270
10.
Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs.
J Pharmacol Toxicol Methods;
56(2): 131-44, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17689270
11.
Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs.
J Pharmacol Toxicol Methods;
53(2): 174-83, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16140023
12.
Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo.
J Cardiovasc Pharmacol Ther;
18(3): 290-300, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23307834
13.
Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
J Pharmacol Toxicol Methods;
63(1): 40-6, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-20451633
14.
New pharmacological targets and treatments for atrial fibrillation.
Trends Pharmacol Sci;
31(8): 364-71, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20605645
15.
Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes.
Stem Cell Res;
4(3): 189-200, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20303332
16.
Improvement of cardiac efficacy and safety models in drug discovery by the use of stem cell-derived cardiomyocytes.
Expert Opin Drug Discov;
4(4): 357-72, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23485039
17.
Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
Drug Discov Today;
14(7-8): 358-72, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19162219
18.
Report and recommendations of the workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity.
Cardiovasc Toxicol;
9(3): 107-25, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19572114
19.
Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009.
J Cardiovasc Pharmacol;
46(1): 7-17, 2005 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15965349
20.
Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009.
J Cardiovasc Electrophysiol;
16(3): 329-41, 2005 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-15817095